Genetic and Immunologic Basis of COVID-19 Infection
Completed
- Conditions
- Genetic Basis of COVID-19 Infection
- Registration Number
- NCT04384250
- Lead Sponsor
- Mansoura University
- Brief Summary
We will study genetic factors causing severe disease due to infection with SARS-COV-2 which may help to find targeted therapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- severe COVID-19 infection
Exclusion Criteria
- Comorbidity ((DM, hypertension, Chronic liver or Kidney diseases, HIV, morbid obesity, Malignancy, Immunosuppressive therapy)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mutations leading to increase susceptibility to SARS-COV-2 infection 12 months Genetic susceptibility to COVID-19
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What genetic variants are associated with severe COVID-19 outcomes in NCT04384250?
How do host genetic factors influence immune response to SARS-CoV-2 in this trial?
What biomarkers predict severe disease progression in SARS-CoV-2-infected patients from NCT04384250?
Are there genetic factors linked to adverse events in SARS-CoV-2 patients studied in NCT04384250?
What molecular targets identified in NCT04384250 could lead to new therapies for severe COVID-19?
Trial Locations
- Locations (1)
Mansoura University
🇪🇬Mansoura, Dakahlyia, Egypt